Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study

The Lancet HIV

Volumn 3, Issue 12, 2016, Pages e592-e600

  Olney, Jack J ^a   Braitstein, Paula ^b,c   Eaton, Jeffrey W ^a   Sang, Edwin ^d   Nyambura, Monicah ^d   Kimaiyo, Sylvester ^d   McRobie, Ellen ^a   Hogan, Joseph W ^e   Hallett, Timothy B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOI UNIVERSITY   (Kenya)

^d ACADEMIC MODEL PROVIDING ACCESS TO HEALTHCARE AMPATH   (Kenya)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COUNSELING; EVALUATION AND FOLLOW UP; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; KENYA; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; POINT OF CARE TESTING; PRIORITY JOURNAL; YOUNG ADULT; ACQUIRED IMMUNODEFICIENCY SYNDROME; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION STUDY; HEALTH CARE DELIVERY; HIV INFECTIONS; PATHOPHYSIOLOGY; QUALITY ADJUSTED LIFE YEAR; STATISTICS AND NUMERICAL DATA;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; COUNSELING; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; KENYA; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS;

EID: 84996843183     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(16)30120-5     Document Type: Article

References (35)

1. 1 UNAIDS. The gap report, 2014, UNAIDS http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport (accessed Aug 3, 2016).
2. 2 Bor, J, Herbst, AJ, Newell, ML, Bärnighausen, T, Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339 (2013), 961–965.
3. 3 Johnson, LF, Mossong, J, Dorrington, RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med, 10, 2013, e1001418.
4. 4 Rosen, S, Fox, MP, Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med, 8, 2011, e1001056.
5. 5 Nachega, JB, Uthman, OA, del Rio, C, Mugavero, MJ, Rees, H, Mills, EJ, Addressing the Achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis 59:suppl 1 (2014), S21–S27.
6. 6 Hallett, TB, Eaton, JW, A side door into care cascade for HIV-infected patients?. J Acquir Immune Defic Syndr 63 (2013), S228–S232.
7. 7 Geng, EH, Bangsberg, DR, Musinguzi, N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr, 53, 2010, 405.
8. 8 Govindasamy, D, Meghij, J, Negussi, EK, Baggaley, RC, Ford, N, Kranzer, K, Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low- and middle-income settings—a systematic review. J Int AIDS Soc, 17, 2014, 19032.
9. 9 van Rooyen, H, Barnabas, RV, Baeten, JM, et al. High HIV testing uptake and linkage to care in a novel program of home based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr, 64, 2013, e1.
10. 10 Jani, IV, Sitoe, NE, Alfai, ER, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 378 (2011), 1572–1579.
11. 11 WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV, 2015, World Health Organization, Geneva.
12. 12 Eaton, JW, Menzies, NA, Stover, J, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health 2 (2014), e23–e34.
13. 13 UNAIDS. 90–90–90—an ambitious treatment target to help end the AIDS epidemic, 2014, UNAIDS http://www.unaids.org/en/resources/documents/2014/90–90–90 (accessed Aug 3, 2016).
14. 14 HIV Modelling Consortium Treatment as Prevention Editorial Writing Group. HIV treatment as prevention: models, data, and questions–towards evidence-based decision-making. PLoS Med, 9, 2012, e1001259.
15. 15 Genberg, BL, Naanyu, V, Wachira, J, et al. Linkage to and engagement in HIV care in western Kenya: an observational study using population-based estimates from home-based counselling and testing. Lancet HIV 2 (2015), e20–e26.
16. 16 Wright, RJ, Stringer, JS, Rapid testing strategies for HIV-1 serodiagnosis in high-prevalence African settings. Am J Prev Med 27 (2004), 42–48.
17. 17 Tagar, E, Sundaram, M, Condliffe, K, et al. Multi-country analysis of treatment costs for HIV/AIDS (MATCH): unit costing at 161 representative facilities in Ethiopia, Malawi, Rwanda, South Africa and Zambia. Harvard Dataverse. http://hdl.handle.net/1902.1/18843 (accessed Aug 3, 2016).
18. 18 Larson, B, Schnippel, K, Ndibongo, B, Long, L, Fox, MP, Rosen, S, How to estimate the cost of point-of-care CD4 testing in program settings: an example using the Alere Pima Analyzer in South Africa. PLoS One, 7, 2012, e35444.
19. 19 Lester, RT, Ritvo, P, Mills, EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 376 (2010), 1838–1845.
20. 20 Rosen, S, Ketlhapile, M, Cost of using a patient tracer to reduce loss to follow-up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa. Trop Med Int Health 15:suppl 1 (2010), 98–104.
21. 21 Fairall, L, Bachmann, MO, Lombard, C, et al. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet 380 (2012), 889–898.
22. 22 Barton, GR, Fairall, L, Bachmann, MO, et al. Cost-effectiveness of nurse-led versus doctor-led antiretroviral treatment in South Africa: pragmatic cluster randomised trial. Trop Med Int Health 18 (2013), 769–777.
23. 23 Sarna, A, Luchters, S, Geibel, S, et al. Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr 48 (2008), 611–619.
24. 24 World Bank. Kenya GDP per capita (2013 USD). http://data.worldbank.org/indicator/NY.GDP.PCAP.CD (accessed Aug 3, 2016).
25. 25 Woods, B, Revill, P, Sculpher, M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP109_cost-effectiveness_threshold_LMICs.pdf, 2015 (accessed Aug 3, 2016).
26. 26 Ochalek, J, Lomas, J, Claxton, K, et al. Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data. https://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP122_cost_DALY_LMIC_threshold.pdf, 2015 (accessed Aug 3, 2016).
27. 27 WHO. Cost effectiveness and strategic planning (WHO-CHOICE), 2014, World Health Organization, Geneva.
28. 28 MacPherson, P, Lalloo, DG, Webb, EL, et al. Effect of optional home initiation of HIV care following HIV self-testing on antiretroviral therapy initiation among adults in Malawi: a randomized clinical trial. JAMA 312 (2014), 372–379.
29. 29 Slaymaker, E, Zaba, B, Mclean, E, et al. Scale and distribution of excess deaths among HIV positive adults by diagnosis, care and treatment history in African population based cohorts 2007–2011. AIDS 2014, Melbourne, Australia. http://pag.aids2014.org/Abstracts.aspx?AID=3347 (accessed Aug 3, 2016).
30. 30 Burns, DN, DeGruttola, V, Pilcher, CD, et al. Toward an endgame: finding and engaging people unaware of their HIV-1 infection in treatment and prevention. AIDS Res Hum Retroviruses 30 (2014), 217–224.
31. 31 Cambiano V, Bertagnolio S, Jordan M, et al. Effectiveness of potential improvements in the cascade of HIV treatment and care in South Africa. Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; March 3–6, 2014. Abstract 1066.
32. 32 Bendavid E, Mills E, Kanters S, Nsanzimana S. Epidemiologic benefits and cost-effectiveness of improving Rwanda's HIV care cascade. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23–26, 2015. Abstract 1109.
33. 33 Klein, DJ, Bershteyn, A, Eckhoff, PA, Dropout and re-enrollment: implications for epidemiological projections of treatment programs. AIDS 28 (2014), S47–S59.
34. 34 Meiners-Chabin C, Pati Pascom A, Araujo de Freitas M, Girade Correa R, Mesquista F. Towards the sustainable implementation of treatment as prevention (TasP) in Brazil: investing in policy measures to cut down on ART costs. 20th International AIDS Conference; Melbourne, Australia; July 20–25, 2014. Abstract WEPW399.
35. 35 Danel C, Moh R, Gabillard D, et al. Early ART and IPT in HIV-infected African adults with high CD4 count (Temprano trial). Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 23–26, 2015.